1. Home
  2. HBNC vs ARDX Comparison

HBNC vs ARDX Comparison

Compare HBNC & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Horizon Bancorp Inc.

HBNC

Horizon Bancorp Inc.

HOLD

Current Price

$19.55

Market Cap

962.4M

Sector

Finance

ML Signal

HOLD

Logo Ardelyx Inc.

ARDX

Ardelyx Inc.

HOLD

Current Price

$3.89

Market Cap

996.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HBNC
ARDX
Founded
1873
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
962.4M
996.8M
IPO Year
1995
2014

Fundamental Metrics

Financial Performance
Metric
HBNC
ARDX
Price
$19.55
$3.89
Analyst Decision
Buy
Strong Buy
Analyst Count
4
7
Target Price
$21.00
$15.14
AVG Volume (30 Days)
589.9K
4.5M
Earning Date
04-22-2026
04-30-2026
Dividend Yield
3.57%
N/A
EPS Growth
N/A
N/A
EPS
1.00
N/A
Revenue
N/A
$2,607,000.00
Revenue This Year
N/A
$37.75
Revenue Next Year
$5.52
$34.24
P/E Ratio
$19.59
N/A
Revenue Growth
N/A
N/A
52 Week Low
$14.97
$3.86
52 Week High
$21.04
$8.40

Technical Indicators

Market Signals
Indicator
HBNC
ARDX
Relative Strength Index (RSI) 36.83 27.70
Support Level $19.12 N/A
Resistance Level $19.93 $6.16
Average True Range (ATR) 0.33 0.19
MACD -0.15 -0.02
Stochastic Oscillator 8.05 4.44

Price Performance

Historical Comparison
HBNC
ARDX

About HBNC Horizon Bancorp Inc.

Horizon Bancorp (IN) is a United States-based holding company providing banking services. It is engaged in providing commercial and retail banking services, corporate and individual trust and agency services, and other services incident to banking. The company also provides commercial loans, real estate loans, mortgage warehouse loans, consumer loans, and other credit facilities. The company has one principal business segment, commercial banking.

About ARDX Ardelyx Inc.

Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.

Share on Social Networks: